Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062832) TIGIT ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/062832 International Application No.: PCT/CN2018/108246
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
C07K 16/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
江苏恒瑞医药股份有限公司 JIANGSU HENGRUI MEDICINE CO., LTD. [CN/CN]; 中国江苏省连云港市 经济技术开发区昆仑山路7号 No.7 Kunlunshan Road, Economic and Technological Development Zone Lianyungang, Jiangsu 222047, CN
上海恒瑞医药有限公司 SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. [CN/CN]; 中国上海市 闵行区文井路279号 No.279 Wenjing Road, Minhang District Shanghai 200245, CN
Inventors:
付雅媛 FU, Yayuan; CN
曹卓晓 CAO, Zhuoxiao; CN
胡齐悦 HU, Qiyue; CN
陶维康 TAO, Weikang; CN
Agent:
北京戈程知识产权代理有限公司 GE CHENG & CO., LTD.; 中国北京市 东城区东长安街1号东方广场东三办公楼19层程伟 David W. CHENG Level 19, Tower E3, the Towers, Oriental Plaza, No.1, East Chang An Avenue, Dongcheng District Beijing 100738, CN
Priority Data:
201710908565.329.09.2017CN
Title (EN) TIGIT ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE THEREOF
(FR) ANTICORPS TIGIT, FRAGMENT DE LIAISON À L'ANTIGÈNE DE CELUI-CI, ET SON UTILISATION MÉDICALE
(ZH) TIGIT抗体、其抗原结合片段及医药用途
Abstract:
(EN) A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.
(FR) L'invention concerne un anticorps TIGIT, un fragment de liaison à l'antigène de celui-ci et son utilisation médicale. La présente invention concerne un anticorps murin, un anticorps chimère, et un anticorps humanisé comprenant une région CDR de l'anticorps TIGIT, ainsi qu'une composition pharmaceutique comprenant l'anticorps TIGIT ou un fragment de liaison à l'antigène de celui-ci, et son utilisation en tant que médicament. En particulier, la présente invention concerne également l'utilisation d'un anticorps TIGIT humanisé dans la préparation d'un médicament pour le traitement de maladies ou d'affections induites par TIGIT.
(ZH) 一种TIGIT 抗体、其抗原结合片段及医药用途。进一步地,还涉及包含所述TIGIT 抗体CDR 区的鼠源抗体、嵌合抗体、人源化抗体,以及包含TIGIT 抗体及其抗原结合片段的药物组合物,以及其作为药物的用途。特别地,还涉及一种人源化的TIGIT 抗体在制备用于治疗TIGIT 相关的疾病或病症的药物中的用途。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)